Integra LifeSciences reports Q2 adjusted EPS 45c, consensus 43c

Reports Q2 revenue $415.6M, consensus $395.06M. “I am proud of our team’s performance and execution in the second quarter. Our strong revenue performance is a testament to our disciplined progress and the solid underlying demand trends for our portfolio of neurosurgery and tissue technology products,” said Mojdeh Poul, president and chief executive officer. “Our transformation is underway, and I’m encouraged by the focused implementation and steady progress made against our Compliance Master Plan. Importantly, we have now completed the assessment phase at all of our manufacturing sites. Looking ahead, we are committed to advancing our remediation efforts, delivering on our commitments, and establishing the foundation of operational excellence required to position Integra for predictable and sustainable growth and profitability over the long-term.”